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Dual antiplatelet therapy facilitated treatment of acute coronary syndromes and enabled
the wide use of stents after clopidogrel emerged on the market about twenty years ago.
Although this was a milestone in cardiology, clopidogrel inherits several disadvantages
which are likely to reduce clinical benefit of its use and a new generation of drugs
including prasugrel and ticagrelor is now available. One megatrial was done for each
substance and various publications regarding subgroups have been published. Since these
broad data is difficult to overview, especially for clinicians not focused on cardiology
patients, the invasive centers of Styria aimed to design an easy-to use algorithm for dual
antiplatelet therapy in ACS. The algorithm divides patients with acute coronary syndromes
into STEMI patients with preferred use of prasugrel and NSTEMI patients being preferen-
tially treated with ticagrelor. Only two subgroups were included to facilitate the use of the
algorithm. Recommended treatment in diabetic patients is the use of prasugrel and
ticagrelor is recommended in small and old patients.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Dual antiplatelet therapy facilitated treatment of acute cor-
onary syndromes and enabled the wide use of stents after
clopidogrel emerged on the market about twenty years ago.
Although this was a milestone in cardiology, clopidogrel
inherits several disadvantages which are likely to reduce
clinical benefit of its use.
First, there is a significant interindividual variability of
platelet inhibition due to genetic polymorphisms in CYP2C19
[1] resulting in less effective platelet inhibition after clopido-
grel administration and which are especially frequent in
Caucasians. The GRAVITAS trial revealed that even dose
adaption after platelet function testing did not improve
cardiovascular outcome [2].
Second, clopidogrel has to be metabolized before inhibi-
ting platelet function. This step needs time and might be
further prolonged in clinical states of hemodynamic instabil-
ity. Increasing loading doses of 300 mg and 600 mg are
recommended to shorten the period to significant plate-
let inhibition, however, the metabolic steps towards the
active metabolite still consume time which can take longer
than the invasive therapy including stenting, resulting in
implanted stents without active dual platelet inhibition until
clopidogrel is converted into active metabolites to a signifi-
cant extent.
Therefore, pharmacological companies put a lot of effort in
developing new drugs overcoming these drawbacks and two of
these drugs delivered positive data in recent megatrials. Both,
prasugrel and ticagrelor significantly improved outcome in
ACS patients compared to clopidogrel. This led to newACS
NSTE-ACS
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Fig. 1 – Flow chart of the styrian ACS consensus. Upon diagn
patients. Patients with NSTE-ACS and comorbidity of diabetes
patients shift to the ticagrelor branch. Immediate initiation of t
ACS patients should only be treated with dual platelet therapy
diagnose of NSTEMI since only in patients with positive troponrecommendations in the latest guidelines which suggest the
preferred use of the new drugs in ACS [3,4]. However, a
comparative trial of both substances is neither ongoing nor
planned and register data is still weak. One therefore has to
decide between the two new substances based on the two
megatrials PLATO and TRITON-TIMI 38 and their substudies as
well as on experimental and pathophysiological data which
drug to use in which patient. Since these broad data is difficult
to overview, especially for clinicians not focused on cardiology
patients, the invasive centers of Styria aimed to design an
easy-to use algorithm for dual antiplatelet therapy in ACS
(Fig. 1). It has to be mentioned that the underlying trials
recruited different cohorts and used different pre-specified
subgroups and thus are not perfectly comparable, leaving all
suggestions drawn from this data in a subjective environment.
A basic idea underlying this algorithm was that an early
onset of antiplatelet therapy is beneficial in ACS. Therefore,
use of the new and faster acting substances is recommended
in these patients and administration of these substances in
the preclinical setting is encouraged, if diagnosis of myocardial
infarction is safe or very likely. This approach follows the ESC
guideline recommendation for NSTE-ACS to ‘‘add a P2Y12
inhibitor as soon as possible’’ although the same table of the
same guideline only recommends prasugrel use after knowing
coronary anatomy because this was part of the study protocol
in TRITON-TIMI 38. Typical ST-elevation will lead to the
diagnosis of STEMI in the vast majority of cases and the drug
can be administered early on a regular basis. In suspected
NSTE-ACS, however, far more differential diagnoses need to be
considered and early administration is only recommended if
the physician dealing with the first medical contact is con-
fident of the diagnosis NSTE-ACS.STEMI
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ose of ACS patients are seperated in STEMI and NSTE-ACS
shift to the prasugrel branch whereas old and small STEMI
herapy is recommended in STEMI patients whereas NSTE-
in presence of a positive troponin or a clinically very likely
in ticagrelor has shown beneficial effects in the PLATO trial.
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The decision to prefer prasugrel in STEMI patients is based
on STEMI substudies of both megatrials [5,6]. Hazard ratio
compared to clopidogrel are 0.79 (0.65–0.97) and 0.87
(0.75–1.01) for prasugrel and ticagrelor, respectively. Moreover,
prasugrel administration resulted in a more pronounced reduc-
tion of HR in STEMI compared to NSTE-ACS patients (0.79 vs.
0.83) whereas ticagrelor was more potent in NSTE-ACS patients
compared to STEMI patients (0.83 for NSTE-ACS and 0.87 for
STEMI). The main beneficial effects of the two drugs seem to
occur at different time points. Whereas prasugrel reduced HR
within the first 3 days beneficial effects of ticagrelor get more
pronounced over the following moths. These data support that
the main effects of ticagrelor may not relate to rapidity of acute
reperfusion but rather prevention of recurrent vascular events
known to modulate long term outcome (Armstrong et al.,
Circulation 125 (2012) 514–521). Moreover, in STEMI patients the
number needed to treat (NNT) was 42 for prasugrel but 71 for
ticagrelor [7]. Although this appears to be solid data it has to be
acknowledged that in TRITON-TIMI 38 an untypical large num-
ber of STEMI were subacute. Especially these patients exerted the
strongest benefit from prasugrel treatment. Therefore, positive
effects might be overestimated compared to a real life setting.
The opposite argumentation was basis of the recommen-
dation of ticagrelor in NSTE-ACS patients. Since these
patients had a larger profit than STEMI patients with tica-
grelor but less effect with prasugrel, ticagrelor seems to have
advantages comparing both new drugs in NSTE-ACS. We
believe that this still holds true even though HR is 0.83 and
NNT is 46 for NSTE-ACS both in PLATO and in TRITON-TIMI
38 [7]. The argumentation in favor of ticagrelor in NSTE-ACS
is based on different patient’s population and the fact that
positive effects on mortality were only seen in PLATO
although STEMI patients had less benefit compared to prasu-
grel treated patients in TRITON-TIMI 38.
2.1. Diabetes
Although many subgroups were evaluated in both megatrials
only diabetes represents a subgroup large enough and with
relevant differences between the two new drugs. Whereas HR
is even more reduced in diabetic patients with prasugrel (HR
0.70 vs. 0.86), diabetic and non-diabetic patients do not show
different results using ticagrelor (0.88 with medical history
of diabetes vs. 0.83 without diabetes). HR further declines
with prasugrel if diabetes is treated with drugs (0.74) or even
more so if it is insulin-dependent diabetes mellitus (0.63).
This underlines the idea of a pathophysiological mechanism
being treated with prasugrel, however, p-value for interaction
did not reach significance due to small numbers of diabetic
patients. Nevertheless, these effects were the basis for the
decision to recommend prasugrel for all diabetic patients
including patients with NSTE-ACS.
2.2. Old and small patients
The algorithm is complicated by warnings in the product
information for prasugrel made by the company. This is due toa predefined subgroup of patients older than 75 years, smaller
than 60 kg and with history of TIA or stroke in TRITON-TIMI38.
These patients did show a worse outcome with prasugrel
compared to clopidogrel. Although these negative effects result
almost completely from TIA/stroke patients the predefined
subgroup results in the actual warning and was adopted in the
Styrian algorithm to prevent potential legal problems. In addi-
tion, despite the product information of prasugrel suggests using
5mg/d maintenance dose in small and old patients this is not
recommended in the algorithm since this suggestion only bases
on pharmacokinetic data and no clinical study has evaluated
this approach so far. It has to be noted that ticagrelor must not
be used, too, in patients with history of intracerebral bleeding
whereas patients with history of TIA did not show impaired
outcome with ticagrelor.3. Discussion
The situation that only STEMI but not NSTE-ACS can be
diagnosed with high likelihood in preclinical settings and the
algorithm favors prasugrel for STEMI patients it has been
discussed if ticagrelor was needed on the ambulance vehicle
at all. The decision to have both drugs in store was made due
to two reasons. First, depending on the physician working on
the ambulance vehicle it is likely that NSTE-ACS is proposed
to be very likely due to typical clinical signs, ECG alterations
and possibly qualitative troponin testing. In such a setting
immediate start of ticagrelor therapy is supposed to be
beneficial. Second, there is no data on switching the two
new platelet-function inhibitors which would be necessary if
prasugrel was given in a NSTE-ACS patient preclinically but
later switched to ticagrelor due to better long term data in
NSTE-ACS.
Another topic under discussion was the need to store
clopidogrel on the ambulance vehicle anymore. If all poten-
tial ACS patients were either treated with only aspirin in
case that ACS was not very likely and dual anti-platelet
therapy was only given after definite diagnosis in the clinic
or immediate dual platelet therapy including the two new
substances, there would be no need to have clopidogrel
anymore. However, three groups of patients have been
identified in which clopidogrel is preferred; first, patients
with atrial fibrillation, second, patients with mechanic
valves and third, patients with thrombolysis. In the first
two groups loading dose of one of the new drugs was
considered to be of justifiable risk in STEMI or high risk
NSTE-ACS patients if clopidogrel was used for chronic
treatment as part of triple therapy (together with aspirin
and oral anticoagulation, or considering the data of the
WOEST study presented at the ESC 2012 clopidogrel and
oral anticoagulation alone). On the other hand, in low risk
patients single therapy with aspirin in the preclinical setting
and consecutive administration of clopidogrel loading in the
hospital was regarded to be reasonable. For the rather small
but important group of patients treated with thrombolysis
there is no data available using the two new drugs and
clopidogrel is recommended in these patients to be used
early. The Styrian algorithm therefore recommends having
clopidogrel on board, too. To simplify drug use on the
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packages one tablet of 300 mg clopidogrel (recommended
dose if thrombolysis is given) can be sticked to each vial for
thrombolysis and administered simultaneously.
The consensus did not differentiate therapy based on
potential side effects or estimated compliance. Nevertheless,
it has to be kept in mind that ticagrelor has additional side
effects compared to former therapy using clopidogrel due to
its modulation of adenosine receptors which can lead to
dyspnea and bradycardia. Both have been observed in PLATO
more often in the ticagrelor group, however, without affecting
total outcome. Therefore, patients with known chronic
obstructive pulmonary disease or known bradycardia should
rather be treated with prasugrel. Furthermore, compliance
might be more difficult in daily practice with ticagrelor as it
has to be taken twice daily.
Comparing bleeding complications in PLATO and TRITON-TIMI
38 indicates higher bleeding complications with prasugrel,
mainly due to fewer coronary artery bypass grafts (CABG) related
bleedings in the ticagrelor group. In this context it has to be
mentioned that bleeding definitions were different in the two
groups and emergency CABG (at the day of myocardial infarc-
tion) was rare. In our hands both new drugs show significantly
increased bleeding during emergency CABG compared to clopi-
dogrel. However, emergency CABG remains a small group of
patients and patients treated with PCI with beneficial effects
outweigh this disadvantage of the new drugs.4. Conclusion
The presented algorithm was designed on the basis of published
trials as well as pathophysiological and pharmacological con-
cepts. The recommendation of the ESC guidelines to administer
dual platelet inhibition ‘‘as soon as possible’’ was weighted
higher than the recommendation to use prasugrel only after
knowing the coronary status (following the study design). The
latter recommendations had to be made following the rules of
evidence based medicine.The algorithm is thought to be differentiated enough to
maximize the benefit even for relevant subgroups but still
easy enough to be feasible for non-cardiologists, too.
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